{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:24:03Z","timestamp":1791422643065,"version":"4.3.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"crossref","award":["T32LM012420-03"],"award-info":[{"award-number":["T32LM012420-03"]}],"id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"crossref","award":["T32-HS000032"],"award-info":[{"award-number":["T32-HS000032"]}],"id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jval.2020.05.019","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T21:31:07Z","timestamp":1596835867000},"page":"1292-1299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Joehl T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A.","family":"Leech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jval.2020.05.019_bib2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:\u00a05-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"5.5","key":"10.1016\/j.jval.2020.05.019_bib5","first-page":"611","article-title":"NCCN guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia","volume":"17","author":"Shah","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.jval.2020.05.019_bib6","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of\u00a0treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jval.2020.05.019_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","article-title":"Selecting the best frontline treatment in chronic myeloid leukemia","volume":"10","author":"Yilmaz","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.jval.2020.05.019_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib11","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JOP.19.00301","article-title":"Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib","volume":"16","author":"Cole","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.jval.2020.05.019_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.jval.2020.05.019_bib13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2020.05.019_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.hoc.2014.08.002","article-title":"Chronic myeloid leukemia-transplantation in the tyrosine kinase era","volume":"28","author":"Innes","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.jval.2020.05.019_bib16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.05.019_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","article-title":"Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies","volume":"23","author":"Briggs","year":"2002","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.jval.2020.05.019_bib22","series-title":"Cost-Effectiveness Analysis in Health: A Practical Approach","author":"Muennig","year":"2008"},{"issue":"7","key":"10.1016\/j.jval.2020.05.019_bib23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2020.05.019_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","article-title":"Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience","volume":"12","author":"Chamoun","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jval.2020.05.019_bib25","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.jval.2020.05.019_bib26","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jval.2020.05.019_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3109\/10428194.2015.1122779","article-title":"Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase","volume":"57","author":"Akard","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jval.2020.05.019_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","article-title":"First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI","volume":"59","author":"Saglio","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jval.2020.05.019_bib29","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jval.2020.05.019_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jval.2020.05.019_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2014.12.003","article-title":"How we will treat chronic myeloid leukemia in 2016","volume":"29","author":"Talati","year":"2015","journal-title":"Blood Rev"}],"updated-by":[{"DOI":"10.1016\/j.jval.2020.10.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T17:07:56Z","timestamp":1604941676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520321732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1098301520321732"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.05.019","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jval.2020.10.007","asserted-by":"object"}]},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}